Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)

Hershman, D. L., Chen, B. E., Sathe, C., Parulekar, W. R., Lemieux, J., Ligibel, J. A., Gelmon, K. A., Whelan, T. J., & Goodwin, P. J. (2023). Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). Breast Cancer Research and Treatment, 200(1), 93–102. https://doi.org/10.1007/s10549-023-06922-2
Authors:
Dawn L Hershman
Bingshu E Chen
Claire Sathe
Wendy R Parulekar
Julie Lemieux
Jennifer A Ligibel
Karen A Gelmon
Timothy J Whelan
Pamela J Goodwin
Affiliated Authors:
Dawn L Hershman
Claire Sathe
Columbia Affiliation:
Subjects:
Breast Neoplasms (MeSH)
Metformin (MeSH)
Author Keywords:
hormonal therapy
medication adherence
metformin
elink
Publication Type:
Article
Unique ID:
10.1007/s10549-023-06922-2
PMID:
37157006
DOI:
10.1007/s10549-023-06922-2
Journal:
Breast Cancer Research and Treatment
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: